Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Choose and initiate an SSRI for an evidence-based anxiety, obsessive-compulsive or trauma indication, explain delayed benefit and early activation, monitor suicide and serious adverse effects, and stop treatment gradually.
Before prescribing, name the target disorder and outcome. SSRIs have evidence across several anxiety and obsessive-compulsive presentations, but choice and dose are indication specific. Review previous benefit and harm, concurrent psychological care, bipolar or manic history, suicide risk, pregnancy or breastfeeding, age, hepatic and renal function, bleeding, sodium risk, cardiac history and all prescribed, over-the-counter and recreational serotonergic substances. Explain common gastrointestinal, sleep and sexual effects and the possibility of emotional blunting. A shared plan records starting dose, titration, first review and stop criteria.
Activation is a clinically important early cluster of increased anxiety, agitation, restlessness and sleep difficulty. Akathisia is a compelling inner restlessness with observable pacing or inability to sit and can be mistaken for the anxiety disorder worsening. Ask directly about suicidal thoughts, impulsivity and new behaviour, not just mood. Review timing against initiation or dose increase and assess mania, stimulant use and serotonin toxicity. Depending on severity and preference, options may include closer monitoring, slower titration, dose reduction, change or cessation; marked or prolonged akathisia or dangerous symptoms require urgent review.
Anxiety, agitation or insomnia begins or intensifies soon after treatment starts or the dose increases, before therapeutic benefit.
Subjective inner restlessness with pacing, rocking or inability to remain seated may create severe distress and suicidal thinking.
Increased energy, reduced need for sleep, accelerated thought and disinhibition represent a qualitative shift rather than simple anxiety activation.
Clonus and hyperreflexia with agitation, autonomic change or hyperthermia after serotonergic exposure distinguish a potentially life-threatening syndrome.
Dizziness, electric-shock sensations, vivid dreams, nausea or rapidly altered mood after reduction may be new and temporally unlike relapse.
Monitor activation, akathisia, suicide risk, mania, bleeding, hyponatraemia, sexual dysfunction and serotonin toxicity; review CYP interactions and avoid MAOIs, and taper gradually to minimise withdrawal.
The maximum is 10 mg daily in adults over 65 and in hepatic impairment; assess QT prolongation, hyponatraemia, bleeding, activation, suicide risk, mania, sexual effects and serotonergic interactions.
Expected early anxiety still needs direct assessment because severe akathisia, suicidality, mania and toxicity require specific action.
The same sertraline product starts lower for panic, PTSD and social anxiety than for adult OCD, reducing avoidable early adverse effects.
Rapid onset after reduction, unfamiliar physical symptoms and a qualitatively different experience make withdrawal more likely than immediate disorder recurrence.
People may not volunteer reduced libido, delayed orgasm or genital sensory change, yet these effects strongly influence adherence and preference.
A routine age-based interval never replaces earlier or more frequent contact when current behaviour, intent, instability or poor support increases risk.
Starting the same dose for every indication despite product-specific lower initiation for panic, PTSD and social anxiety.
Describing activation as harmless without assessing akathisia, suicide risk, mania, stimulant use and serotonin toxicity.
Using a prescription record as proof of an adequate course without checking doses actually taken and adverse-effect barriers.
Stopping early because benefit is absent before the expected disorder-specific response period, particularly in OCD.
Stopping abruptly after long treatment or using equal large reductions down to zero despite worsening withdrawal at low doses.
Your practice draft is saved in this browser.
An adult chooses sertraline for newly diagnosed panic disorder. Which licensed starting regimen is designed to reduce early treatment-emergent adverse effects?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Monitoring follows both indication and individual risk. NICE GAD and social-anxiety guidance tells prescribers to warn people under 30 about increased suicidal thinking and self-harm in a minority, review within one week and monitor weekly for the first month. OCD guidance calls for careful frequent monitoring in younger adults, comorbid depression or increased suicide risk and active enquiry about akathisia, anxiety and agitation. Depression guidance uses review at one week for ages eighteen to twenty-five or increased suicide risk. Higher baseline risk always overrides a routine interval.
Response is not immediate. Early adverse effects can precede benefit; OCD may take up to twelve weeks. Titrate no faster than the selected SmPC, compare symptoms and function with baseline and verify actual adherence. Continue effective treatment for the disorder-specific maintenance period: at least twelve months for GAD or OCD in their NICE pathways and at least six months after the optimal dose is reached for panic disorder. When stopping, explain withdrawal, use a slow stepwise reduction proportionate to the current dose with smaller decrements near the end, and pause or reduce the decrement if intolerable symptoms emerge.